Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database (CovPCR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04738331
Recruitment Status : Recruiting
First Posted : February 4, 2021
Last Update Posted : May 26, 2021
Sponsor:
Information provided by (Responsible Party):
University Hospital, Montpellier

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Analysing ths spread of COVID-19 epidemics in a timely manner is key to implementing public health control strategies. The investigators propose to analyse a large set of laboratory SARS-CoV-2 RT-PCR data to explore potential links between Ct values and epidemic parameters.

Condition or disease
Covid-19 SARS-CoV Infection

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10000000 participants
Observational Model: Other
Time Perspective: Retrospective
Official Title: Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database : CovPCR
Actual Study Start Date : February 1, 2021
Estimated Primary Completion Date : May 20, 2022
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Detecting co-factors associated with Ct values [ Time Frame: 1 day ]
    Detecting co-factors associated with Ct values


Secondary Outcome Measures :
  1. Detecting associations with epidemic spread [ Time Frame: 1 day ]
    Detecting associations with epidemic spread


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
French population with a RT-PCR test for SARS-Cov2 infection
Criteria

Inclusion criteria:

- A SARS-Cov2 RT-PCR result with a known sampling date

Exclusion criteria:

- Patient refusing to participate in research

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04738331


Contacts
Layout table for location contacts
Contact: Samuel Alizon, PhD 610654902 ext 33 samuel.alizon@cnrs.fr
Contact: Vincent Foulongne, PhD 467 330 254 ext 33 v-foulongne@chu-montpellier.fr

Locations
Layout table for location information
France
Uh Montpellier Recruiting
Montpellier, France, 34295
Contact: Vincent Foulongne, PHD    467 330 254 ext 33    v-foulongne@chu-montpellier.fr   
Sponsors and Collaborators
University Hospital, Montpellier
Investigators
Layout table for investigator information
Study Director: Vincent Foulongne, PhD UH MONTPELLIER
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT04738331    
Other Study ID Numbers: RECHMPL21_0051
First Posted: February 4, 2021    Key Record Dates
Last Update Posted: May 26, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: NC

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Montpellier:
SARS-Cov2 infection
Tested for SARS-Cov2 infection with RT-PCR test
CT
epidemiology
reproduction number
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
COVID-19
Severe Acute Respiratory Syndrome
Respiratory Tract Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases